Mylan (NASDAQ:MYL) Director Robert J. Coury sold 50,000 shares of the business’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $43.41, for a total transaction of $2,170,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Robert J. Coury also recently made the following trade(s):
- On Friday, March 2nd, Robert J. Coury sold 150,000 shares of Mylan stock. The shares were sold at an average price of $40.10, for a total transaction of $6,015,000.00.
Shares of Mylan (NASDAQ MYL) traded down $0.33 during trading hours on Wednesday, reaching $42.02. 3,160,000 shares of the company’s stock traded hands, compared to its average volume of 5,560,000. The company has a quick ratio of 0.73, a current ratio of 1.13 and a debt-to-equity ratio of 1.06. Mylan has a 52-week low of $29.39 and a 52-week high of $47.82. The company has a market cap of $21,800.00, a PE ratio of 32.32, a PEG ratio of 1.36 and a beta of 1.35.
Mylan (NASDAQ:MYL) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $1.43 EPS for the quarter, topping the consensus estimate of $1.41 by $0.02. The firm had revenue of $3.24 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Mylan had a net margin of 5.84% and a return on equity of 19.14%. The company’s revenue for the quarter was down .9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.57 EPS. research analysts expect that Mylan will post 5.38 EPS for the current year.
A number of brokerages recently weighed in on MYL. TheStreet raised shares of Mylan from a “c” rating to a “b-” rating in a research note on Wednesday, January 17th. Citigroup reaffirmed a “buy” rating and issued a $58.00 target price (up from $48.00) on shares of Mylan in a research note on Thursday, January 4th. Guggenheim began coverage on shares of Mylan in a research note on Tuesday, December 12th. They issued a “buy” rating and a $59.00 target price for the company. UBS Group set a $46.00 target price on shares of Mylan and gave the stock a “buy” rating in a research note on Monday, December 4th. Finally, ValuEngine raised shares of Mylan from a “hold” rating to a “buy” rating in a research note on Friday, December 1st. Nine analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $45.92.
Several hedge funds have recently modified their holdings of MYL. Pzena Investment Management LLC raised its holdings in shares of Mylan by 84.1% in the 3rd quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock valued at $712,770,000 after purchasing an additional 10,381,697 shares during the period. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Mylan in the 4th quarter valued at about $137,023,000. Millennium Management LLC raised its holdings in shares of Mylan by 3,005.3% in the 4th quarter. Millennium Management LLC now owns 2,905,317 shares of the company’s stock valued at $122,924,000 after purchasing an additional 3,005,317 shares during the period. Schroder Investment Management Group raised its holdings in shares of Mylan by 74.7% in the 3rd quarter. Schroder Investment Management Group now owns 3,026,172 shares of the company’s stock valued at $93,388,000 after purchasing an additional 1,294,400 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in shares of Mylan by 30.3% in the 4th quarter. Bank of New York Mellon Corp now owns 5,334,789 shares of the company’s stock valued at $225,715,000 after purchasing an additional 1,239,089 shares during the period. 84.82% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Insider Selling: Mylan (MYL) Director Sells 50,000 Shares of Stock” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://ledgergazette.com/2018/03/15/mylan-myl-director-sells-2170500-00-in-stock.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.